Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex

Executive Summary

Orkambi is the first combo drug to be priced lower than solo therapy with one of its components, but it stands to increase Vertex’s patient base exponentially.

Advertisement

Related Content

Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel